Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL. Hanker AB, et al. Among authors: brase jc. Clin Cancer Res. 2017 Aug 1;23(15):4323-4334. doi: 10.1158/1078-0432.CCR-16-2287. Epub 2017 Apr 5. Clin Cancer Res. 2017. PMID: 28381415 Free PMC article.
HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer.
Denkert C, Huober J, Loibl S, Prinzler J, Kronenwett R, Darb-Esfahani S, Brase JC, Solbach C, Mehta K, Fasching PA, Sinn BV, Engels K, Reinisch M, Hansmann ML, Tesch H, von Minckwitz G, Untch M. Denkert C, et al. Among authors: brase jc. Breast Cancer Res. 2013 Feb 7;15(1):R11. doi: 10.1186/bcr3384. Breast Cancer Res. 2013. PMID: 23391338 Free PMC article.
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, Schem C, Fisch K, Darb-Esfahani S, Mehta K, Sotiriou C, Wienert S, Klare P, André F, Klauschen F, Blohmer JU, Krappmann K, Schmidt M, Tesch H, Kümmel S, Sinn P, Jackisch C, Dietel M, Reimer T, Untch M, Loibl S. Denkert C, et al. Among authors: brase jc. J Clin Oncol. 2015 Mar 20;33(9):983-91. doi: 10.1200/JCO.2014.58.1967. Epub 2014 Dec 22. J Clin Oncol. 2015. PMID: 25534375 Clinical Trial.
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C. Fumagalli D, et al. Among authors: brase jc. JAMA Oncol. 2017 Feb 1;3(2):227-234. doi: 10.1001/jamaoncol.2016.3824. JAMA Oncol. 2017. PMID: 27684533 Free PMC article.
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, Fasani R, Paré L, Oliveira M, Galvan P, Martínez N, Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, Manso L, Alarcón J, Martínez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E. Nuciforo P, et al. Among authors: brase jc. Ann Oncol. 2018 Jan 1;29(1):170-177. doi: 10.1093/annonc/mdx647. Ann Oncol. 2018. PMID: 29045543 Free article.
Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A, Brase JC, Cheng Y, Nuciforo P, Paré L, Pascual T, Martínez D, Galván P, Vidal M, Adamo B, Hortobagyi GN, Baselga J, Ciruelos E. Prat A, et al. Among authors: brase jc. Oncologist. 2019 Jul;24(7):893-900. doi: 10.1634/theoncologist.2018-0407. Epub 2019 Jan 24. Oncologist. 2019. PMID: 30679318 Free PMC article. Clinical Trial.
Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL. Hanker AB, et al. Among authors: brase jc. Clin Cancer Res. 2019 Feb 15;25(4):1434. doi: 10.1158/1078-0432.CCR-18-4267. Clin Cancer Res. 2019. PMID: 30770493 No abstract available.
BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer.
Middleton G, Yang Y, Campbell CD, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, De Vos F, Van Cutsem E, Millholland JM, Brase JC, Rangwala F, Gasal E, Corcoran RB. Middleton G, et al. Among authors: brase jc. Clin Cancer Res. 2020 Jun 1;26(11):2466-2476. doi: 10.1158/1078-0432.CCR-19-3579. Epub 2020 Feb 11. Clin Cancer Res. 2020. PMID: 32047001 Free PMC article.
A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.
Prat A, Tsai YH, Pascual T, Paré L, Adamo B, Vidal M, Brasó-Maristany F, Galván P, Brase JC, Rodrik-Outmezguine V, Johnston S, Ciruelos E, Parker JS. Prat A, et al. Among authors: brase jc. Clin Cancer Res. 2020 Dec 1;26(23):6141-6148. doi: 10.1158/1078-0432.CCR-20-2793. Epub 2020 Sep 22. Clin Cancer Res. 2020. PMID: 32962980 Clinical Trial.
52 results